Revenue Breakdown
Composition ()
No data
Revenue Streams
MaxCyte Inc (MXCT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product, accounting for 57.9% of total sales, equivalent to $3.95M. Other significant revenue streams include Product sales and Licenses. Understanding this composition is critical for investors evaluating how MXCT navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, MaxCyte Inc maintains a gross margin of 61.34%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -164.81%, while the net margin is -181.81%. These profitability ratios, combined with a Return on Equity (ROE) of -23.19%, provide a clear picture of how effectively MXCT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MXCT competes directly with industry leaders such as MCRB and MAIA. With a market capitalization of $86.54M, it holds a leading position in the sector. When comparing efficiency, MXCT's gross margin of 61.34% stands against MCRB's 100.00% and MAIA's N/A. Such benchmarking helps identify whether MaxCyte Inc is trading at a premium or discount relative to its financial performance.
